- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kyowa Kirin Co Ltd (4151)
Kyowa Kirin Co Ltd stock price live, this page displays TYO 4151 stock exchange data. View the 4151 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kyowa Kirin Co Ltd real time stock price chart below.
What Is the Kyowa Kirin Co Ltd Stock Price Today?
The Kyowa Kirin Co Ltd stock price today is 2,526.5.
What Is the Stock Symbol for Kyowa Kirin Co Ltd?
The stock ticker symbol for Kyowa Kirin Co Ltd is 4151.
Is 4151 the Same as $4151?
$4151 is a common way to refer to the Kyowa Kirin Co Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Kyowa Kirin Co Ltd Trade On?
Kyowa Kirin Co Ltd is listed and trades on the Tokyo stock exchange.
Is Kyowa Kirin Co Ltd a Good Stock to Buy?
Determining whether Kyowa Kirin Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Kyowa Kirin Co Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4151 quote. (ISIN: JP3256000005)
What Is the Kyowa Kirin Co Ltd Stock Price Today?
The Kyowa Kirin Co Ltd stock price today is 2,526.5.
What Is the Stock Symbol for Kyowa Kirin Co Ltd?
The stock ticker symbol for Kyowa Kirin Co Ltd is 4151.
Is 4151 the Same as $4151?
$4151 is a common way to refer to the Kyowa Kirin Co Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Kyowa Kirin Co Ltd Trade On?
Kyowa Kirin Co Ltd is listed and trades on the Tokyo stock exchange.
Is Kyowa Kirin Co Ltd a Good Stock to Buy?
Determining whether Kyowa Kirin Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Kyowa Kirin Co Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4151 quote. (ISIN: JP3256000005)
2,526.0
+4.5(+0.18%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,500.0
2,546.5
52 wk Range
2,091.5
2,912.0
4151 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,500.02,546.5
52 wk Range
2,091.52,912.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.66%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.66%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
4151 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
2,140.9
Downside
-15.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 9 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Kyowa Kirin Co Ltd Earnings Call Summary for Q2/2025
- Kyowa Kirin missed Q2 2025 forecasts with EPS of ¥31.1 (14.68% below expectations) and revenue of ¥118.8 billion; interim profit plunged 57% to ¥16.3 billion
- Despite financial underperformance, the company's stock rose 3.57% in after-hours trading, suggesting investor confidence in restructuring efforts
- ¥9.4 billion in extraordinary expenses from an early retirement program and reduced drug prices in Japan contributed to the 21% drop in core operating profit
- Management maintained full-year guidance and emphasized AI integration and global strategic products as key growth drivers amid Japanese market challenges
- CEO Miyamoto reaffirmed commitment to 'Vision 2030' strategic plan while acknowledging risks from Japan's population decline and an increasingly competitive pharmaceutical landscape
Last Updated: 11/16/2025, 04:26 PM
Read Full TranscriptKyowa Kirin investor slides for Q2/2025
Last Update: Nov 16, 2025
See full investor slides
Compare 4151 to Peers and Sector
Metrics to compare | 4151 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4151PeersSector | |
|---|---|---|---|---|
P/E Ratio | 19.7x | 19.8x | −0.5x | |
PEG Ratio | 1.50 | 0.57 | 0.00 | |
Price / Book | 1.5x | 1.9x | 2.6x | |
Price / LTM Sales | 2.7x | 2.2x | 3.2x | |
Upside (Analyst Target) | −20.7% | 9.3% | 45.7% | |
Fair Value Upside | Unlock | 10.7% | 4.8% | Unlock |
Analyst Ratings
2 Buy
3 Hold
6 Sell
Ratings:
11 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 2,140.9
(-15.25% Downside)
Earnings
Latest Release
Feb 09, 2026
EPS / Forecast
65.79 / 47.54
Revenue / Forecast
147.38B / 132.05B
People Also Watch
FAQ
What Is the Kyowa Kirin (4151) Stock Price Today?
The Kyowa Kirin stock price today is 2,526.0 JPY.
What Stock Exchange Does Kyowa Kirin Trade On?
Kyowa Kirin is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for Kyowa Kirin?
The stock symbol for Kyowa Kirin is "4151."
Does Kyowa Kirin Pay Dividends? What’s The Current Dividend Yield?
The Kyowa Kirin dividend yield is 2.66%.
What Is the Kyowa Kirin Market Cap?
As of today, Kyowa Kirin market cap is 1.32T JPY.
What Is Kyowa Kirin's Earnings Per Share (TTM)?
The Kyowa Kirin EPS (TTM) is 128.1.
When Is the Next Kyowa Kirin Earnings Date?
Kyowa Kirin will release its next earnings report on May 07, 2026.
From a Technical Analysis Perspective, Is 4151 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Kyowa Kirin Stock Split?
Kyowa Kirin has split 0 times.
How Many Employees Does Kyowa Kirin Have?
Kyowa Kirin has 5161 employees.
What is the current trading status of Kyowa Kirin (4151)?
As of Apr 16, 2026, Kyowa Kirin (4151) is trading at a price of 2,526.0 JPY, with a previous close of 2,521.5 JPY. The stock has fluctuated within a day range of 2,500.0 JPY to 2,546.5 JPY, while its 52-week range spans from 2,091.5 JPY to 2,912.0 JPY.
What Is Kyowa Kirin (4151) Price Target According to Analysts?
The average 12-month price target for Kyowa Kirin is 2,140.9 JPY, with a high estimate of 3100 JPY and a low estimate of 1600 JPY. 2 analysts recommend buying the stock, while 6 suggest selling, leading to an overall rating of Neutral. The stock has an -15.25% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.